Abstract
Hemoglobin vesicle (HbV), a liposomal oxygen carrier containing human hemoglobin, was intravenously infused into rats. After the infusion of saline, the HbV or empty vesicle (EV), numbers of red cells, leukocytes and platelets in peripheral blood were unchanged during the observation period of one week in addition to each time point among three groups. However, the lymphocyte ratio transiently decreased and the granulocyte ratio increased in the HbV and EV groups at 6 h after the infusion. Those changes returned to the initial value one day after the infusion and those were maintained for the subsequent observation period. No dramatic change was seen in the ratio of CD4 +/CD8+ T cells. A transient decrease of the complement titer was observed three days after the infusion of HbV and EV, although the consumption of complement titer was not detected in rat serum by mixing HbV or EV in vitro, indicating that the transient decrease of complement titer in vivo was not due to the consumption of complement due to the interaction with HbV or EV. Multiple infusions of HbV caused the decrease of complement titer only after the first infusion and no allergic reaction was observed. No anaphylactic shock was observed in rats administered with EV several times, while ovalbumin (OVA) sensitized rats died with symptoms of respiratory distress after the second OVA administration. These results indicate that HbV could be administered without serious clinical symptoms or adverse reactions.
| Original language | English |
|---|---|
| Pages (from-to) | 157-172 |
| Number of pages | 16 |
| Journal | Artificial Cells, Blood Substitutes, and Biotechnology |
| Volume | 35 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - 2007 Mar |
Fingerprint
Keywords
- Anaphylaxis
- Complement
- Hematological response
- Hemoglobin vesicle
- Liposome
ASJC Scopus subject areas
- Biotechnology
- Biomedical Engineering
- Hematology
Cite this
Effects of hemoglobin vesicles, a liposomal artificial oxygen carrier, on hematological responses, complement and anaphylactic reactions in rats. / Abe, Hideki; Azuma, Hiroshi; Yamaguchi, Miki; Fujihara, Mitsuhiro; Ikeda, Hisami; Sakai, Hiromi; Takeoka, Shinji; Tsuchida, Eishun.
In: Artificial Cells, Blood Substitutes, and Biotechnology, Vol. 35, No. 2, 03.2007, p. 157-172.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Effects of hemoglobin vesicles, a liposomal artificial oxygen carrier, on hematological responses, complement and anaphylactic reactions in rats
AU - Abe, Hideki
AU - Azuma, Hiroshi
AU - Yamaguchi, Miki
AU - Fujihara, Mitsuhiro
AU - Ikeda, Hisami
AU - Sakai, Hiromi
AU - Takeoka, Shinji
AU - Tsuchida, Eishun
PY - 2007/3
Y1 - 2007/3
N2 - Hemoglobin vesicle (HbV), a liposomal oxygen carrier containing human hemoglobin, was intravenously infused into rats. After the infusion of saline, the HbV or empty vesicle (EV), numbers of red cells, leukocytes and platelets in peripheral blood were unchanged during the observation period of one week in addition to each time point among three groups. However, the lymphocyte ratio transiently decreased and the granulocyte ratio increased in the HbV and EV groups at 6 h after the infusion. Those changes returned to the initial value one day after the infusion and those were maintained for the subsequent observation period. No dramatic change was seen in the ratio of CD4 +/CD8+ T cells. A transient decrease of the complement titer was observed three days after the infusion of HbV and EV, although the consumption of complement titer was not detected in rat serum by mixing HbV or EV in vitro, indicating that the transient decrease of complement titer in vivo was not due to the consumption of complement due to the interaction with HbV or EV. Multiple infusions of HbV caused the decrease of complement titer only after the first infusion and no allergic reaction was observed. No anaphylactic shock was observed in rats administered with EV several times, while ovalbumin (OVA) sensitized rats died with symptoms of respiratory distress after the second OVA administration. These results indicate that HbV could be administered without serious clinical symptoms or adverse reactions.
AB - Hemoglobin vesicle (HbV), a liposomal oxygen carrier containing human hemoglobin, was intravenously infused into rats. After the infusion of saline, the HbV or empty vesicle (EV), numbers of red cells, leukocytes and platelets in peripheral blood were unchanged during the observation period of one week in addition to each time point among three groups. However, the lymphocyte ratio transiently decreased and the granulocyte ratio increased in the HbV and EV groups at 6 h after the infusion. Those changes returned to the initial value one day after the infusion and those were maintained for the subsequent observation period. No dramatic change was seen in the ratio of CD4 +/CD8+ T cells. A transient decrease of the complement titer was observed three days after the infusion of HbV and EV, although the consumption of complement titer was not detected in rat serum by mixing HbV or EV in vitro, indicating that the transient decrease of complement titer in vivo was not due to the consumption of complement due to the interaction with HbV or EV. Multiple infusions of HbV caused the decrease of complement titer only after the first infusion and no allergic reaction was observed. No anaphylactic shock was observed in rats administered with EV several times, while ovalbumin (OVA) sensitized rats died with symptoms of respiratory distress after the second OVA administration. These results indicate that HbV could be administered without serious clinical symptoms or adverse reactions.
KW - Anaphylaxis
KW - Complement
KW - Hematological response
KW - Hemoglobin vesicle
KW - Liposome
UR - http://www.scopus.com/inward/record.url?scp=34047167529&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34047167529&partnerID=8YFLogxK
U2 - 10.1080/10731190601188224
DO - 10.1080/10731190601188224
M3 - Article
C2 - 17453702
AN - SCOPUS:34047167529
VL - 35
SP - 157
EP - 172
JO - Artificial Cells, Nanomedicine and Biotechnology
JF - Artificial Cells, Nanomedicine and Biotechnology
SN - 2169-1401
IS - 2
ER -